Gallium PET for PRRT of NET
Edition 8/8 of the Webinar Series on Present and Future of NET Management
Kindly supported by AAA

Brief summary of contents

This webinar describes the role of 68Ga-DOTATATE PET/CT in the diagnostic algorithm of NETs, explains the technique and the interpretation, illustrating the pearls and the pitfalls, in view of patient selection for PRRT. PRRT history and current results are also presented. Finally, assessment of the molecular genomics, to be possibly integrated with molecular imaging to amplify therapeutic personalization and efficacy prediction, is presented.

Content: Presentation and MCQ test (10 questions)
Length: 00:28:17 min

View
(7)
Principles of Theranostic in NET: diagnosis and therapy with labelled peptides
Edition 7/8 of the Webinar Series on Present and Future of NET Management
Kindly supported by AAA

Brief summary of contents
This lecture illustrates the 20 years  research experience  in PRRT of Prof Giovanni Paganelli  and his group . The presentation is focused on the personalized treatment of GEP-NET  according to the presence of risk factors for kindey and bone marrow toxicity. Moreover,  the role of  FDG PET as a prognostic indicator and patient’s stratification is also addressed.

Content: Presentation and MCQ test (15 questions)
Length: 00:32:36 min

View
(6)
PRRT of NET
Edition 6/8 of the Webinar Series on Present and Future of NET Management
Kindly supported by AAA

Brief summary of contents

This webinar deals with the rationale of PRRT in neuroendocrine tumors, with the management of patients and when PRRT should be offered to NET patients and how it can be performed. 

After the discussion of theoretical aspects, 4 representative clinical cases will be proposed.

A conclusion with key points (take home messages) is presented.

Content: Presentation and MCQ test (10 questions)
Length: 00:36:18 min



View
(2)
Clinical Impact of Gallium PET/CT in NET
Edition 5/8 of the Webinar Series on Present and Future of NET Management
Kindly supported by AAA

Brief summary of contents

The diagnosis of neuroendocrine tumours is based on a combination imaging, biochemistry and histology. Nuclear medicine plays a key role in diagnosis and therapy for these tumours. Historically In-DTPA Octreotide scan was used for imaging to aid diagnosis and determine suitability for PRRT. There has been recent advances with development of a number of Ga-68 PET tracers. The most widely published is Ga-68 DOTATATE PET. This webinar describes the role of Ga-68 PET imaging in clinical practice and its impact on clinical care. We demonstrate the role in Ga-68 in altering clinical decisions including identifying small primary sites of disease, low volume recurrent disease. Also identifying patients suitable for PRRT.

Content: Presentation and MCQ test (9 questions)
Length: 00:40:07 min



View
(No ranking yet)
How to report 68Gallium PET/CT for SSR
Edition 4/8 of the Webinar Series on Present and Future of NET Management
Kindly supported by AAA

Brief summary of contents

The webinar will include tips for providing an accurate and informative report. In addition, a overview of physiologic distribution and possible sources of false positive findings on 68Ga-labeled peptides PET will be provided. Lastly, challenges and opportunities for future developments will be discussed.


Content: Presentation and MCQ test (4 questions)
Length: 00:28:31 min



View
(1)
PET and SPECT Tracers to image NET
Edition 3/8 of the Webinar Series on Present and Future of NET Management
Kindly supported by AAA

Brief summary of contents
Nuclear Medicine procedures have been used with great success for studying Gastro-Entero-Pancreatic (GEP) Neuroendocrine Tumours (NET). Several SPECT and PET tracers were found useful for evaluation of NET, allowing to image different characterisctics of these neoplasms. Tracers based on radiolabelled somatostatin analogs were introduced to study NET expressing a high density of somatostatin receptors (SSR) and gained a widespread acceptance, especially for GEP NET. SSR SPECT has been used routinely for studying carcinoids and other NETs for years, while PET tracers were introduced more recently for the imaging of NET. Other tracers have been developed to evaluate the different metabolic pathways of NETs, such as F-DOPA, C-HTP.
The webinar is reporting the principles of different radiotracers to image NET, discussing the literature data as well as presenting examples from author’s files.

Content: Presentation and MCQ test (11 questions)
Length: 00:33:30 min



View
(No ranking yet)
68Gallium PET/CT Image acquisition and reconstruction
Edition 2/8 of the Webinar Series on Present and Future of NET Management
Kindly supported by AAA

Brief summary of contents
The content is a light scientific synopsis of Gallium-68 PET/CT image acquisition and reconstruction. Its aim is to give an understanding and appreciation of the processes and issues surrounding the subject matter.


Content: Presentation and MCQ test (10 questions)
Length: 00:21:15 min



View
(No ranking yet)
Preparation of Gallium PET radio tracers (TATE – TOC – NOC)
Edition 1/8 of the Webinar Series on Present and Future of NET Management
Kindly supported by AAA

Brief summary of contents
This webinar gives a basic information on 68Ga-Somatostatin analogues DOTA-TOC, -TATE, -NOC for Positron Emission Tomography (PET) application.  This includes an introduction to Gallium and its properties, bifunctional chelators and the peptides used for PET Somatostatin receptor imaging. Information on generators and radiolabelling techniques with 68Ga including automated systems and kit technologies are provided and finally quality control for 68Ga Somatostatin analogues is described.

Content: Presentation and MCQ test (14 questions)
Length: 00:31:08 min



View
(2)